High in-vivo stability in preclinical and first-in-human experiments with [18F]AlF-RESCA-MIRC213: a 18F-labeled nanobody as PET radiotracer for diagnosis of HER2-positive cancers
Author:
Publisher
Springer Science and Business Media LLC
Subject
Radiology, Nuclear Medicine and imaging,General Medicine,Radiology, Nuclear Medicine and imaging,General Medicine
Link
https://link.springer.com/content/pdf/10.1007/s00259-022-05967-7.pdf
Reference56 articles.
1. Cai Y, Wang J, Zhang L, et al. Expressions of fatty acid synthase and HER2 are correlated with poor prognosis of ovarian cancer. Med Oncol. 2015;32(1):391.
2. Schluter B, Gerhards R, Strumberg D, et al. Combined detection of HER2/neu gene amplification and protein overexpression in effusions from patients with breast and ovarian cancer. J Cancer Res Clin Oncol. 2010;136(9):1389–400.
3. Ménard S, Casalini P, Campiglio M, et al. HER2 overexpression in various tumor types, focusing on its relationship to the development of invasive breast cancer. Ann Oncol. 2001;12:S15–9.
4. Scholl S, Beuzeboc P, Pouillart P. Targeting HER2 in other tumor types. Ann Oncol. 2001;12:S81–7.
5. Buonaguro FM, Lewis GK, Pelicci P. Introducing infectious agents and cancer. Infect Agent Cancer. 2006;1(1):1.
Cited by 10 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. “Nanobody-based immunodiagnostics: A systematic review of nanobody integration in diagnostics and deep insight into electrochemical immunoassays”;Microchemical Journal;2024-01
2. Innovative strategies to study epigenetic regulation and advance precision medicine;Comprehensive Precision Medicine;2024
3. Engineered polyspecific antibodies: A new frontier in the field of immunotherapeutics;Immunology;2023-12-23
4. Preclinical evaluation and pilot clinical study of [68Ga]Ga-THP-APN09, a novel PD-L1 targeted nanobody radiotracer for rapid one-step radiolabeling and PET imaging;European Journal of Nuclear Medicine and Molecular Imaging;2023-08-09
5. Current status and future expectations of nanobodies in oncology trials;Expert Opinion on Investigational Drugs;2023-08-03
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3